• 1. 華西醫(yī)科大學(xué)附屬第一醫(yī)院普外科研究生，現(xiàn)在四川省腫瘤醫(yī)院乳腺外科(成都610041)2. 華西醫(yī)科大學(xué)附屬第一醫(yī)院普外科3. 四川省人民醫(yī)院外一科;

為探討測定乳腺癌細(xì)胞內(nèi)雌激素受體(ER)，以判斷腫瘤對內(nèi)分泌治療的敏感性和預(yù)后，利用125碘標(biāo)記17α-乙烯雌二醇-3-醋酸酯(125IVE2A)在不同ER含量的荷人乳腺癌裸鼠體內(nèi)進(jìn)行生物學(xué)分布研究，觀察其與受體含量的關(guān)系，為進(jìn)一步進(jìn)行腫瘤ER顯像奠定基礎(chǔ)。每只鼠尾靜脈注射示蹤劑92.5 kBq，2小時后處死，測定其腫瘤及重要組織器官每克組織中放射性攝取率及腫瘤與非腫瘤放射性比值(T/NT)。結(jié)果表明： 在ER為陽性的腫瘤(MCF-7)，其放射性攝取率及放射性比值均高于ER陰性腫瘤(MDA-MB-231)的相應(yīng)值，且分布具選擇性，雌激素靶器官選擇性高，非靶器官選擇性低。125IVE2A對ER陽性的腫瘤及子宮具親和力，可望用作對體內(nèi)ER進(jìn)行定位定量測定。

引用本文： 龍啟明,楊金巧,陳曉理,胡銳,周蕾蕾. 125碘標(biāo)記17α-乙烯雌二醇-3-醋酸酯在荷人乳腺癌裸鼠體內(nèi)生物學(xué)分布. 中國普外基礎(chǔ)與臨床雜志, 1999, 6(5): 266-267. doi: 復(fù)制

1. Joan HM. Hormone receptors and breast cancer. Human Pathol, 1981; 12(12)∶1057.
2. Nakatsuka I, Ferreira NL, Eckelman WC, et al. Synthesis and evaluation of (17α， 20E)21〔125I〕iodo19norpregna1,3,5(10), 20tetraene3, 17diol and (17α, 20E)21〔125I〕iodo11βmethoxy19norpregna1,3,5(10), 20tetraene3, 17diol 17α(iodovingl) estradiol derivatives as high specific activity potential radiopharmaceuticals. J Med Chem, 1984; 27(10)∶1287.
3. Eckelman WC, Reba RC, Gibson RE, et al. Receptor binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med, 1979; 20(2)∶350.
4. EU PJ, Khan O. Emission computerised tomography: clinical application. Semi in Nucl Med, 1981; 11(1)∶50.
5. Cummins CH. Radiolabeled steroid estrogens in cancer research. Steroid, 1993; 58(2)∶245.
6. Symes EK, Bishop PB, Coulson WF, et al. 17αZ〔125I〕 iodovingloestradiol and its 3acetate: chemical synthesis and in vivo distribution studies in the rat. Biochem Parmacol, 1992; 44(4)∶741.
7. Zeicher M, Delcorde A, Quivy J, et al. Radioimaging of human breast carcinoma xenografts in mice by 〔123I〕lebeled Z17αiodovingl11βchloromethy estradiol. Nucl Med Biol, 1996; 23(1)∶69.
8. McManaway ME, Jagodo EM, Kasid A, et al. 〔125I〕17αiodovingl 11βmethoxyestradiol interaction in vivo with estrogen receptors in hormoneindependent MCF7 human breast cancer transfected with the VrasH oncogene. Cancer Res, 1987; 47(11)∶2945.
  1. 1. Joan HM. Hormone receptors and breast cancer. Human Pathol, 1981; 12(12)∶1057.
  2. 2. Nakatsuka I, Ferreira NL, Eckelman WC, et al. Synthesis and evaluation of (17α， 20E)21〔125I〕iodo19norpregna1,3,5(10), 20tetraene3, 17diol and (17α, 20E)21〔125I〕iodo11βmethoxy19norpregna1,3,5(10), 20tetraene3, 17diol 17α(iodovingl) estradiol derivatives as high specific activity potential radiopharmaceuticals. J Med Chem, 1984; 27(10)∶1287.
  3. 3. Eckelman WC, Reba RC, Gibson RE, et al. Receptor binding radiotracers: a class of potential radiopharmaceuticals. J Nucl Med, 1979; 20(2)∶350.
  4. 4. EU PJ, Khan O. Emission computerised tomography: clinical application. Semi in Nucl Med, 1981; 11(1)∶50.
  5. 5. Cummins CH. Radiolabeled steroid estrogens in cancer research. Steroid, 1993; 58(2)∶245.
  6. 6. Symes EK, Bishop PB, Coulson WF, et al. 17αZ〔125I〕 iodovingloestradiol and its 3acetate: chemical synthesis and in vivo distribution studies in the rat. Biochem Parmacol, 1992; 44(4)∶741.
  7. 7. Zeicher M, Delcorde A, Quivy J, et al. Radioimaging of human breast carcinoma xenografts in mice by 〔123I〕lebeled Z17αiodovingl11βchloromethy estradiol. Nucl Med Biol, 1996; 23(1)∶69.
  8. 8. McManaway ME, Jagodo EM, Kasid A, et al. 〔125I〕17αiodovingl 11βmethoxyestradiol interaction in vivo with estrogen receptors in hormoneindependent MCF7 human breast cancer transfected with the VrasH oncogene. Cancer Res, 1987; 47(11)∶2945.